We are a clinical-stage biotechnology startup company specializing in

CRISPR-based precision genome editing medicine. We focus on delivering affordable

one-and-done in-body “DNA surgery” for genetic diseases with unmet needs. 

GenEditBio
現時募資階段:
種子
投資年份:
2024 HK GBA Fund
類別:
AI/Healthcare
創辦人:
Zongli ZHENG, Tian ZHU